Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

2231.187 - 2256.103 Dr. Andrea Apolo

I don't know the answer to that, but I do tell you that initially I was, when a patient got checkpoint and they develop metastatic disease, I was moving on to EV alone, but The more I thought about it and the more I discussed it with patients, I think that there's a synergy with EV plus Pembro and I think that it's reasonable to try to intensify the treatment that they're receiving.